The impact of hypogonadism and autonomic dysfunction on fatigue, emotional function, and sexual desire in male patients with advanced cancer - A pilot study

被引:80
作者
Strasser, Florian
Palmer, J. Lynn
Schover, Leslie R.
Yusuf, S. Wamique
Pisters, Katherine
Vassilopoulou-Sellin, Rena
DeGracia, Beth
Willey, Jie S.
Bruera, Eduardo
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Palliat Care & Rehabil Med, Houston, TX 77030 USA
[2] Cantonal Hosp, Dept Internal Med, Hematol Oncol Sect, St Gallen, Switzerland
[3] Univ Texas, MD Anderson Canc Ctr, Dept Behav Sci, Houston, TX 77030 USA
[4] Univ Texas, MD Anderson Canc Ctr, Dept Cardiol, Houston, TX 77030 USA
[5] Univ Texas, MD Anderson Canc Ctr, Dept Thorac Med Oncol, Houston, TX 77030 USA
[6] Univ Texas, MD Anderson Canc Ctr, Dept Endocrinol, Houston, TX 77030 USA
关键词
hypogonadism; autonomic dysfunction; fatigue; emotional distress; sexual function; palliative care;
D O I
10.1002/cncr.22339
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. The objective of this study was to determine whether hypogonadism and autonomic dysfunction contribute substantially to cancer-related fatigue, decreased sexual desire, and depression in male patients with advanced, incurable cancer. METHODS. Forty-eight patients who had received no major antineoplastic intervention for at least 2 weeks were tested for autonomic dysfunction by using Ewing tests. Total and free testosterone levels were measured. Multivariate analyses were performed to test the relation of these factors with the Functional Assessment of Cancer Therapy (FACT) (the Functional Assessment of Anorexia/Cachexia Therapy [FAACT] scale and the Functional Assessment of Chronic Illness Therapy-Fatigue [FACIT-F] subscale), the Hospital Anxiety and Depression Scale (HADS), the Edmonton Symptom Assessment Scale, the Sexual Desire Inventory, and sexual function (Cancer Rehabilitation Evaluation System subscale). Common causes for fatigue (anemia, depression, malnutrition, symptom distress, and medications) also were considered. RESULTS. Thirty-eight of 47 patients (81'70) had autonomic dysfunction, although it was not associated significantly with the other variables examined. 7lventy-nine of 45 patients (64%) had a low level of free testosterone (hypogonadism), which was correlated with the HADS Anxiety score (P=.002), the FACT Emotional Well-Being score (P=.02), and the HADS Depression score (P=.04). Hypogonadal men also had lower scores on the FACT Functional Well-Being scale (P=.01) and the FACIT-F subscale (P=.05). Men who reported symptoms related to weight loss (FAACT scale) had significantly lower levels of free testosterone (r=0.34; P=.02) but did not differ from the other group in actual weight loss (P =.22). The total testosterone level was not appropriate for screening of hypogonadism unless the patients had values < 100 ng/mL. Logistic regression analysis failed to reveal a distinct multivariate model of autonomic dysfunction or hypogonadism that predicted clinical outcomes. CONCLUSIONS. Hypogonadism is a frequent condition in patients with advanced, incurable cancer and is associated with negative mood, fatigue, and symptoms related to anorexia/cachexia.
引用
收藏
页码:2949 / 2957
页数:9
相关论文
共 53 条
[1]   Endocrine consequences of long-term intrathecal administration of opioids [J].
Abs, R ;
Verhelst, J ;
Maeyaert, J ;
Van Buyten, JP ;
Opsomer, F ;
Adriaensen, H ;
Verlooy, J ;
Van Havenbergh, T ;
Smet, M ;
Van Acker, K .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (06) :2215-2222
[2]   Plasma testosterone and sexual function in men receiving buprenorphine maintenance for opioid dependence [J].
Bliesener, N ;
Albrecht, S ;
Schwager, A ;
Weckbecker, K ;
Lichtermann, D ;
Klingmüller, D .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (01) :203-206
[3]  
Bruera E, 1987, J Pain Symptom Manage, V2, P19, DOI 10.1016/S0885-3924(87)80041-6
[4]  
BRUERA E, 1986, CANCER TREAT REP, V70, P1383
[5]  
Chang VT, 2000, CANCER, V88, P2164, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2164::AID-CNCR24>3.0.CO
[6]  
2-5
[7]   Complications of androgen-deprivation therapy in men with prostate cancer [J].
Chen A.C. ;
Petrylak D.P. .
Current Urology Reports, 2005, 6 (3) :210-216
[8]  
CHLEBOWSKI RT, 1982, CANCER RES, V42, P2495
[9]   Inflammatory biomarkers for persistent fatigue in breast cancer survivors [J].
Collado-Hidalgo, A ;
Bower, JE ;
Ganz, PA ;
Cole, SW ;
Irwin, MR .
CLINICAL CANCER RESEARCH, 2006, 12 (09) :2759-2766
[10]   AUTONOMIC NEUROPATHY - ITS DIAGNOSIS AND PROGNOSIS [J].
EWING, DJ ;
CLARKE, BF .
CLINICS IN ENDOCRINOLOGY AND METABOLISM, 1986, 15 (04) :855-888